Galcanezumab
Galcanezumab (pronounced as gal-ka-nez-u-mab) is a monoclonal antibody designed for the prevention of migraine. It is marketed under the brand name Emgality by Eli Lilly and Company.
Etymology
The name "Galcanezumab" is derived from the International Nonproprietary Names (INN), where "zu" indicates humanized, "mab" stands for monoclonal antibody, and "galca" is a unique stem.
Pharmacology
Galcanezumab works by binding to the calcitonin gene-related peptide (CGRP) and blocking its function. CGRP is a neuropeptide that plays a crucial role in the pathophysiology of migraines. By inhibiting the function of CGRP, Galcanezumab can prevent the onset of migraines.
Usage
Galcanezumab is used for the preventive treatment of migraine in adults. It is administered through subcutaneous injections once a month.
Side Effects
Common side effects of Galcanezumab include injection site reactions, such as pain or redness, and constipation. Serious allergic reactions to Galcanezumab are rare but can occur.
Related Terms
External links
- Medical encyclopedia article on Galcanezumab
- Wikipedia's article - Galcanezumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski